3. What is Synovial Sarcoma?
Synovial sarcoma (SS) is a rare sarcoma driven by a translocation between SS18
and SSX 1, 2, or 4. The hybrid transcription factor SS18:SSX alters
SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling and global
methylation patterns that may allow future therapeutic opportunities.
4. Current treatment of Synovial Sarcoma involves multimodal approach, incorporating surgery,
chemotherapy, and radiotherapy. Currently, surgery remains the mainstay for treatment of synovial
sarcoma. While considering the overall disease management perspective, first-line treatment
usually consists of wide margin surgery plus radiotherapy. However, DelveInsight’s market
forecast model is based entirely on pharmacological therapies and does not include any procedural
or surgical methods.
View Synovial Sarcoma Market Report
5. As per the latest treatment paradigms, chemotherapy regimen is
administered for a fixed number of cycles followed by a watchful
waiting approach to assess the optimum response. Doxorubicin and
ifosfamide constitute the first-line approach generating a large
segment of synovial sarcoma’s chemotherapeutic market.
6. ● The US
● EU5 (Germany, France, Italy, Spain,
and the United Kingdom)
● Japan
How Many Regions Are
Covered?
7. Doxorubicin with or without ifosfamide remains the
mainstay of first-line chemotherapy for synovial
sarcoma treatment although data from recent studies
suggest that SS patients might benefit from first-line
combination treatment of ifosfamide with doxorubicin
over monotherapy doxorubicin. However, due to
rarity of disease, this cannot be considered a final
conclusive result.
8. KOL- Views
To keep up with current market trends, we take KOLs and SME’s opinion working in the
Synovial Sarcoma domain through primary research to fill the data gaps and validate
our secondary research. Their opinion helps understand and validate current and
emerging therapies treatment patterns or Synovial Sarcoma market trends. This will
support the clients in potential upcoming novel treatment by identifying the overall
scenario of the market and the unmet needs.
9. What is the Synovial Sarcoma Market Report
Scope?
● The report covers the descriptive overview of synovial sarcoma, explaining its causes, signs and symptoms,
physiology, and currently available therapies.
● Comprehensive insight has been provided into the synovial sarcoma epidemiology and treatment in the
7MM.
● Additionally, an all-inclusive account of both the current and emerging therapies for synovial sarcoma is
provided, along with the assessment of new therapies, which will impact the current treatment landscape.
● A detailed review of the synovial sarcoma market, historical and forecasted, is included in the report,
covering drug outreach in the 7MM.
● The report provides an edge while developing business strategies by understanding trends shaping and
driving the global synovial sarcoma market.
10. What are the Synovial Sarcoma Market
Report Highlights?
● In the coming years, the synovial sarcoma market is set to change due to the rising awareness of the disease
and the favorable environment for new anti-infective modalities, expanding the market’s size to enable the
drug manufacturers to penetrate more into the market.
● The companies and academics are working to assess challenges and seek opportunities that could influence
synovial sarcoma R&D. The therapies under development are focused on novel approaches to treat/improve
the disease condition.
● Major players are involved in developing therapies for synovial sarcoma. The launch of emerging therapies
will significantly impact the synovial sarcoma market.
● Our in-depth analysis of the pipeline assets across different stages of development (Phase I, II, and III),
different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key
cross-competition, and launch date along with product development activities will support the clients in the
decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the
research and development activities.
11. CREDITS: This presentation template was
created by Slidesgo, including icons by
Flaticon, and infographics & images by
Freepik
Please keep this slide for attribution
info@delveinsight.com
ybhardwaj@delveinsight.com
+91-9650213330
Do You Have Any Question or Query?
12. CREDITS: This presentation template was
created by Slidesgo, including icons by
Flaticon, and infographics & images by
Freepik
Thanks!
